Page 7 - Mark Corbae News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Cybrexa Therapeutics Closes $25 Million Series B Financing -Proceeds will advance the company's lead program into clinical trials- NEW HAVEN, Conn., March 10, 2021 (GLOBE NEWSWIRE) -- Cybrexa Therapeutics, an oncology-focused biotechnology company developing a new class of therapeutics through its alphalex Peptide Drug Conjugate (PDC) tumor targeting platform, today announced the completion of its $25 million Series B financing. The financing included HighCape Capital and new investor Elm Street Ventures. Proceeds from the financing will be used to support the planned advancement of Cybrexa...

(1) - Cybrexa and NCI to collaborate on clinical development of Cybrexa's lead candidate, CBX-12, to assess the safety and efficacy in oncology patients with solid tumors - NEW HAVEN, Conn., Feb. 24, 2021 (GLOBE NEWSWIRE) -- Cybrexa Therapeutics, an oncology-focused biotechnology company developing a new class of therapeutics through its alphalex Peptide Drug Conjugate (PDC) tumor targeting platform, today announced that it has entered a Cooperative Research and Development Agreement (CRADA) with the U.S. National Cancer Institute (NCI), part of the National Institutes of Health. Under term...

Sirnaomics to Present at Medical Dermatology Summit News provided by Share this article , a biopharmaceutical company engaged in the discovery and development of RNAi therapeutics against cancer and fibrotic diseases, today announced that it will be presenting results from a recently completed Phase 2a clinical study of the company's lead drug candidate, STP705, for treatment of squamous cell skin cancer, at the 19th Annual South Beach Symposium Medical Dermatology Summit. The virtual conference runs from Feb. 5-7, 2021. Title: Innovation in the Treatment of NMSC: siRNA STP705 for SCC in situ...

Cybrexa Therapeutics Reports Positive Results from GLP Toxicology Study of Lead Candidate CBX-12 (alphalex-exatecan) - No Unexpected Safety Findings During the Course of the Study - - On Track to File an IND in the First Quarter 2021 and Commence Phase I Trial by Mid Year 2021 - NEW HAVEN, Conn., Jan. 28, 2021 (GLOBE NEWSWIRE) -- Cybrexa Therapeutics, an oncology-focused biotechnology company developing a new class of therapeutics through its alphalex Peptide Drug Conjugate (PDC) tumor targeting platform, today announced that it has completed the GLP toxicology study of its lead candidate, ...

/PRNewswire/ -- Sirnaomics, Inc., a biopharmaceutical company engaged in the discovery and development of RNAi therapeutics against cancer and fibrotic...